Literature DB >> 7699214

Comparison between the suppressive effects of dexamethasone and loperamide on cortisol and ACTH secretion in some pathological conditions.

G P Bernini1, G F Argenio, F Cerri, F Franchi.   

Abstract

Since in patients with Cushing's disease, unlike in normal subjects, tonic inhibitory opioid control of ACTH secretion does not operate, use of the opiate agonist loperamide (LOP) has recently been proposed in the diagnosis of hypercortisolemic states. We compared the sensitivity, specificity and diagnostic accuracy of the LOP test (16 mg orally) with corresponding results of the dexamethasone test (DXM, 1 mg orally overnight) in 23 normal subjects and in a total of 42 patients, affected by Cushing's disease (n = 8), incidentally discovered adrenal masses with impaired function of the hypothalamic-pituitary-adrenal (HPA) axis (n = 6), obesity (n = 21) and depression (n = 7). While in controls both DXM and LOP strongly suppressed plasma cortisol and ACTH, in Cushing's disease and in incidentalomas no patient showed a decrease in cortisol levels below 50 ng/ml or a reduction in plasma cortisol greater than 50% of basal values in response to LOP and DXM. In obese subjects both drugs significantly reduced plasma cortisol and ACTH without giving false positive results. In the depressed group only 3/7 patients showed a decrement in cortisol levels below 50 ng/ml after LOP in contrast to 6/7 after DXM. Thus, in patients with impairment of the HPA-axis, i.e. in Cushing's disease and in patients with adrenal incidentalomas and hormonal abnormalities, LOP and DXM test sensitivity was 100%. In controls and in obese patients specificity was 100% both with LOP and DXM, while in depressed patients it was 43% and 86% with LOP and DXM, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7699214     DOI: 10.1007/BF03347780

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  27 in total

1.  Effects of loperamide on the human hypothalamo-pituitary-adrenal axis in vivo and in vitro.

Authors:  C J Auernhammer; G K Stalla; M Lange; A Pfeiffer; O A Müller
Journal:  J Clin Endocrinol Metab       Date:  1992-08       Impact factor: 5.958

2.  Differences in corticosterone and dexamethasone binding to rat brain and pituitary.

Authors:  R De Kloet; G Wallach; B S McEwen
Journal:  Endocrinology       Date:  1975-03       Impact factor: 4.736

3.  FK 33-824, a met-enkephalin analog, blocks corticotropin-releasing hormone-induced adrenocorticotropin secretion in normal subjects but not in patients with Cushing's disease.

Authors:  B Allolio; U Deuss; D Kaulen; U Leonhardt; D Kallabis; E Hamel; W Winkelmann
Journal:  J Clin Endocrinol Metab       Date:  1986-12       Impact factor: 5.958

4.  Analogies between Cushing's disease and depression: a case report.

Authors:  L Becker; P Gold; G Chrousos
Journal:  Gen Hosp Psychiatry       Date:  1983-07       Impact factor: 3.238

5.  Morphine inhibits the pituitary-adrenal response to ovine corticotropin-releasing hormone in normal subjects.

Authors:  R S Rittmaster; G B Cutler; D O Sobel; D S Goldstein; M C Koppelman; D L Loriaux; G P Chrousos
Journal:  J Clin Endocrinol Metab       Date:  1985-05       Impact factor: 5.958

6.  Effects of the opiate agonist loperamide on pituitary-adrenal function in patients with suspected hypercortisolism.

Authors:  B Ambrosi; D Bochicchio; R Ferrario; P Colombo; G Faglia
Journal:  J Endocrinol Invest       Date:  1989-01       Impact factor: 4.256

Review 7.  Corticosteroid inhibition of ACTH secretion.

Authors:  M E Keller-Wood; M F Dallman
Journal:  Endocr Rev       Date:  1984       Impact factor: 19.871

8.  The hypothalamic-pituitary-adrenal axis in obese women with different patterns of body fat distribution.

Authors:  R Pasquali; S Cantobelli; F Casimirri; M Capelli; L Bortoluzzi; R Flamia; A M Labate; L Barbara
Journal:  J Clin Endocrinol Metab       Date:  1993-08       Impact factor: 5.958

9.  Dexamethasone suppression tests: usefulness of simultaneous measurement of plasma cortisol and dexamethasone.

Authors:  A W Meikle
Journal:  Clin Endocrinol (Oxf)       Date:  1982-04       Impact factor: 3.478

10.  Diagnostic categorization of psychiatric disturbance in Cushing's syndrome.

Authors:  R F Haskett
Journal:  Am J Psychiatry       Date:  1985-08       Impact factor: 18.112

View more
  3 in total

Review 1.  Drugs and HPA axis.

Authors:  Alberto Giacinto Ambrogio; Francesca Pecori Giraldi; Francesco Cavagnini
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

2.  The dexamethasone-suppressed corticotropin-releasing hormone stimulation test differentiates mild Cushing's disease from normal physiology.

Authors:  J A Yanovski; G B Cutler; G P Chrousos; L K Nieman
Journal:  J Clin Endocrinol Metab       Date:  1998-02       Impact factor: 5.958

Review 3.  Hypothalamic-pituitary-adrenal axis dysfunction as a neurobiological correlate of emotion dysregulation in adolescent suicide.

Authors:  María Dolores Braquehais; María Dolores Picouto; Miquel Casas; Leo Sher
Journal:  World J Pediatr       Date:  2012-08-12       Impact factor: 2.764

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.